Pro-inflammatory cytokines and related immune pathways

Pro-inflammatory cytokines and their associated immune pathways represent a broad class of signaling molecules and intracellular cascades that drive the innate and adaptive immune responses. Key players include Tumor necrosis factor-alpha (TNF-alpha), Interleukin-1 (IL-1), and Interleukin-6 (IL-6), which act as primary mediators of systemic inflammation and the acute phase response [Dinarello, 2000]. These cytokines trigger downstream signaling through pathways such as the Janus kinase/signal transducer and activator of transcription (JAK/STAT) and the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappaB) systems, leading to the expression of genes involved in cell proliferation, survival, and recruitment [O'Shea & Plenge, 2012]. While essential for host defense against pathogens, chronic overactivation of these pathways is central to the pathogenesis of numerous autoimmune and chronic inflammatory conditions, including rheumatoid arthritis, inflammatory bowel disease, and psoriasis [Zhang & An, 2007]. Therapeutic strategies in biotechnology focus on high-specificity intervention, such as monoclonal antibodies that neutralize specific ligands or receptors, and small-molecule inhibitors targeting intracellular signaling components. However, modulating these pathways carries significant clinical risks, most notably systemic immunosuppression which predisposes patients to serious opportunistic infections and potential long-term malignancy [StatPearls, 2023].

Other names

Pro-inflammatory mediatorsInflammatory cytokine networkCytokine signaling cascadesPro-inflammatory signaling

Therapeutic agents target this system by neutralizing circulating cytokine ligands (e.g., anti-TNF antibodies), blocking cytokine receptors (e.g., IL-6R antagonists), or inhibiting intracellular signaling enzymes like Janus kinases (JAKs) to prevent the transcription of pro-inflammatory genes [O'Shea & Plenge, 2012].